PARIS, May 27, 2015 /PRNewswire/ --
Boston Scientific Corporation (NYSE: BSX) announces the appointment of Professor John Mark Morgan as senior medical director, Rhythm Management, effective from September 1st, 2015.
Prof. Morgan, an internationally recognised expert clinician in the field of cardiac rhythm management, will help shape and influence the advancement of medical therapies across all areas of the Cardiac Rhythm Management division, with a particular focus on Europe.
Prof. Morgan currently serves as consultant cardiologist, specialist in Cardiac Rhythm Management at University Hospital Southampton NHS Trust, and honorary professor of Cardiac Rhythm Management at the University of Southampton, United Kingdom. He will leave his NHS appointment from September 1st but will continue his academic affiliations.
He has supervised many postdoctoral students, has a research portfolio of more than 300 publications and has made contributions to the understanding of cardiac defibrillation, sudden cardiac death risk stratification and ICD therapy, cardiac resynchronization therapy, use of implantable technologies for the management of heart failure, and treatment of complex arrhythmias, with some particular interest in adult congenital heart disease. Over the past twenty years he has also served in the leaderships of national and international societies in a wide variety of roles as well as advising large corporations in their healthcare technology development strategies and product development.
"I am very happy about Prof. Morgan joining Boston Scientific. He will be instrumental in guiding our clinical strategy and driving innovation in our R&D teams," said Pierre Chauvineau, vice president Europe, Cardiac Rhythm Management, Boston Scientific.
"Prof. Morgan is a key addition to our clinical team and we are looking forward to leveraging his scientific and medical expertise", added Dr Kenneth Stein, chief medical officer, Rhythm Management, Boston Scientific.
Prof. Morgan holds a 1st class honours degree in parts I and II of the Natural Sciences Tripos, graduating from Gonville and Caius College, Cambridge. He undertook his clinical training at Westminster Medical School (now absorbed into Imperial College) graduating MB BChir in 1982. He became a member of the Royal College in 1985 and fellow in 1995 and fellow of the European Society of Cardiology in 2002. He was appointed as honorary senior lecturer, Southampton Medical School in 1999; honorary professor at the University of Teesside in 2006; honorary professor at the School of Medicine, Southampton in 2007; and visiting professor at Imperial College, London in 2014.
"Boston Scientific has an extensive and innovative rhythm management portfolio, with technologies that can be truly regarded as game changers. I am looking forward to starting this new chapter in my professional life, contributing to further develop the Company's clinical strategy," said Prof. Morgan.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit http://www.bostonscientific.eu and connect on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials and impact of data, product performance and impact and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.